BECN1 and prostate carcinoma: And these results were in contrast to Liu et al. (2013) (22), who demonstrated downregulation of Beclin1 in prostatic carcinoma and this contravery in te results might be due to the difference in the number of the studied prostatic carcinoma cases as they use 34 cases only and also the difference in the used technique as they used western blotting assay.